Press Releases

    • MAR 22 2017

    ONC201 Phase I Trial Results Reported in Clinical Cancer Research

    Philadelphia, PA (March 22, 2017) – Oncoceutics, Inc. announced the publication of an original research article in the journal Clinical Cancer Research entitled “First-in-human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors” that describes the Phase I trial of the company’s lead compound at the Rutgers Cancer Institute of New Jersey. The

    • MAR 14 2017

    Oncoceutics Expands DRD2 Research Collaborations with NIH

    Philadelphia, PA (March 14, 2017) – Oncoceutics, Inc., announced a number of new research collaborations with various groups within the National Institutes of Health (NIH) to study DRD2 as a novel therapeutic target in oncology. DRD2, a member of the dopamine receptor family that is part of the G protein-coupled receptor (GPCR) superfamily, is a

    • JAN 31 2017

    Oncoceutics Announces USPTO Reissues Patent with Correct Structure of ONC201

    Philadelphia, PA (January 31, 2017) – Oncoceutics, Inc. announced that the United States Patent and Trademark Office (USPTO) has reissued patent #8,673,923, for the use of the company’s lead molecule ONC201 to treat various brain cancers, to include the correct depiction of the chemical structure of the molecule.  The previous version of the patent, issued

    • DEC 20 2016

    ONC201 Glioblastoma Trial to Expand Based on Promising Initial Results

    Philadelphia, PA (December 20, 2016) – Oncoceutics announced that it will expand the ongoing study with ONC201 in recurrent glioblastoma at Massachusetts General Hospital (MGH) and Dana Farber Cancer Institute (DFCI) that is supported by a National Cancer Institute grant awarded to Oncoceutics.   Between January and April, MGH and DFCI enrolled 17 patients with